Flexion Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.3M
Doctors Paid
10,183
Transactions
37,550
2020 Total
$2.1M
Payment Breakdown by Category
Research$6.6M (58.2%)
Consulting$1.8M (15.8%)
Food & Beverage$867,939 (7.7%)
Travel$349,908 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.6M | 183 | 58.2% |
| Consulting Fee | $1.8M | 502 | 15.8% |
| Honoraria | $1.5M | 613 | 13.5% |
| Food and Beverage | $867,939 | 34,655 | 7.7% |
| Travel and Lodging | $349,908 | 976 | 3.1% |
| Grant | $100,000 | 2 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $91,271 | 29 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,942 | 246 | 0.1% |
| Education | $4,294 | 344 | 0.0% |
Payments by Type
Research
$6.6M
183 transactions
General
$4.7M
37,367 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients with Osteoarthritis of the Knee | $2.6M | 0 | 22 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis | $1.1M | 0 | 58 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis | $661,744 | 0 | 36 |
| A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients with Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip | $386,201 | 0 | 7 |
| An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients with Osteoarthritis of the Knee | $379,060 | 0 | 19 |
| Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee | $322,211 | 0 | 3 |
| Success of Long-acting Anti-inflammatories after anterior cruciate ligament and Meniscal injury SLAM | $194,996 | 1 | 1 |
| Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip | $184,942 | 0 | 11 |
| Benefits of IA Injections | $116,025 | 0 | 2 |
| A study of the Effect of Intraarticular Corticosteroid on Metabolic Syndrome Biomarkers A Pilot Feasibility Study | $109,806 | 1 | 1 |
| Zilretta vs. TAcs | $101,600 | 0 | 1 |
| Rotator Cuff | $82,453 | 0 | 1 |
| Effect of ZILRETTA Injection on Neuromuscular Function, Gait Biomechanics and Physical Performance | $74,012 | 0 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder | $57,625 | 0 | 10 |
| Success of Long-acting Anti-inflammatories after anterior cruciate ligament and Meniscal injury (SLAM) | $48,749 | 0 | 1 |
| An open-label pilot study of the effect of intra-articular bilateral knee injections of Zilretta (FX006) on OARSI recommended physical performance measures in adults with knee osteoarthritis. | $45,156 | 0 | 1 |
| Patient- and Physician-Perceived Barriers to and Benefits of Intraarticular Injections for Osteoarthritis: A Qualitative Study | $29,006 | 0 | 1 |
| A study of the Effect of Intraarticular Corticosteroid on Metabolic Syndrome Biomarkers (A Pilot / Feasibility Study) | $27,452 | 0 | 1 |
| A Stratified Investigation of a Single Injection of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for Symptomatic Relief in Patients with Idiopathic Adhesive Capsulitis of the Shoulder. | $24,529 | 0 | 1 |
| A Randomized, Open-label, Parallel Group Study in Patients with Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration into Both Knees of either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) | $20,687 | 0 | 3 |
| Zilretta for Shoulder IAC | $20,441 | 0 | 1 |
| Study to assess the safety and efficacy of FX006 administered to patients with greater trochanteric bursitis | $15,439 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Dr. Andrew Spitzer, M.d, M.D | Orthopaedic Surgery | Los Angeles, CA | $417,557 | $0 |
| Dr. John Barrington, Md, MD | Adult Reconstructive Orthopaedic Surgery | Plano, TX | $341,563 | $0 |
| Scott Sigman, Md, MD | Orthopaedic Surgery | North Chelmsford, MA | $241,093 | $0 |
| Dr. Austin Stone, M.d., Ph.d, M.D., PH.D | Student in an Organized Health Care Education/Training Program | Lexington, KY | $194,996 | $0 |
| Dr. John Richmond, M.d, M.D | Orthopaedic Surgery | Waltham, MA | $164,150 | $0 |
| Philip Reilly, M.d, M.D | Internal Medicine | Waltham, MA | $136,000 | $0 |
| John Kelly, Md, MD | Orthopaedic Surgery | Philadelphia, PA | $111,010 | $0 |
| Andrew Concoff, Md, MD | Rheumatology | Fullerton, CA | $107,818 | $0 |
| Dr. Nirav Amin, M.d, M.D | Orthopaedic Surgery | Placentia, CA | $101,102 | $0 |
| Jack Bert, Md, MD | Orthopaedic Surgery | Woodbury, MN | $100,282 | $0 |
| Michael Langworthy, Md, MD | Adult Reconstructive Orthopaedic Surgery | North Dartmouth, MA | $89,882 | $0 |
| Dr. Marco Alcala, M.d, M.D | Sports Medicine | Canonsburg, PA | $88,093 | $0 |
| Paul Sethi, M.d, M.D | Orthopaedic Surgery | Greenwich, CT | $83,370 | $0 |
| Dr. Deryk Jones, Md, MD | Sports Medicine | San Carlos, CA | $75,730 | $0 |
| Nirav Gupta, D.o, D.O | Orthopaedic Surgery | Ocala, FL | $72,287 | $0 |
| Mr. Michael Cross, M.d, M.D | Orthopaedic Surgery | Indianapolis, IN | $62,595 | $0 |
| Dr. Paul Saenz, Do, DO | Sports Medicine | San Antonio, TX | $58,701 | $0 |
| Dr. Richard Linn, Md, MD | Specialist | Plantation, FL | $56,434 | $0 |
| Hari Bezwada, Md, MD | Orthopaedic Surgery | Princeton, NJ | $55,812 | $0 |
| Dr. Ira Evans, M.d, M.D | Orthopaedic Surgery | Peabody, MA | $48,066 | $0 |
| Joseph Ruane, Do, DO | Sports Medicine | Columbus, OH | $46,475 | $0 |
| William Maloney | Orthopaedic Surgery | Stanford, CA | $45,106 | $0 |
| Kevin Plancher, Md, MD | Orthopaedic Surgery | New York, NY | $44,797 | $0 |
| Robert Dimeff, Md, MD | Sports Medicine | Dallas, TX | $41,705 | $0 |
| Mark Ian Froimson, Md, MD | Orthopaedic Surgery | Cleveland, OH | $40,476 | $0 |
About Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc. has made $11.3M in payments to 10,183 healthcare providers, recorded across 37,550 transactions in the CMS Open Payments database. In 2020, the company paid $2.1M. The top product by payment volume is Zilretta ($10.0M).
Payments were distributed across 117 medical specialties. The top specialty by payment amount is Orthopaedic Surgery ($2.3M to 3,632 doctors).
Payment categories include: Food & Beverage ($867,939), Consulting ($1.8M), Research ($6.6M), Travel & Lodging ($349,908).
Flexion Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.